Human 2.0: How artificial intelligence is set to "change us" – an overview of science, promises, and pitfalls

The vision of "changing humanity" through artificial intelligence is no longer science fiction – it is a scientific experiment currently in progress. From Neuralink implants to memory-enhancing algorithms, technologies are already modifying how we think, make decisions, and perceive the world. But what do the facts say? What are the realistic prospects, and where do unresolved problems lie? We present an in-depth overview that separates promises from reality.

▶

Ever since Ray Kurzweil announced that humanity would merge with machine intelligence by 2045, the term "human enhancement" has gained the status of a near-religious belief in progress. However, reality is more complex. Current technologies, while revolutionary, are far from fulfilling the "Human 2.0" vision. Moreover, the discussion regarding the integration of AI with the human brain raises not only enthusiasm but also serious ethical, legal, and scientific concerns.

In this article, we have gathered the latest scientific evidence, discussed key technologies, verified deployment timelines, and compared the positions of researchers from around the world. Our goal is not to fearmonger or glorify change – we want to separate speculation from what is already happening today.

Technologies set to "change humanity" – what actually works?

Pearson, a futurist known for books such as Future Human, points to several areas where AI and neurotechnologies are expected to play a key role. To assess how far we are from this vision, let’s look at the three most important categories: brain-computer interfaces (BCI), cognitive enhancement algorithms, and AI-supported gene editing.

1. Brain-computer interfaces (BCI): a bridge between mind and machine

BCI technologies enable direct communication between the human brain and external devices – or vice versa. Their development is progressing in two main directions: invasive (implants) and non-invasive (caps, headbands).

• Neuralink – Elon Musk's company – was the first to receive approval from the U.S. Food and Drug Administration (FDA) in May 2023 for initial human clinical trials. In January 2024, it performed its first implantations in patients with paraplegia, aiming to restore limb control by connecting the brain to external devices. While the goals are noble, the technology still faces challenges: implants are invasive, and their long-term durability and safety remain uncertain.
  Neuralink provides regular progress updates on its website.
• Synchron – a competing approach based on the less invasive Stentrode – a device implanted in the brain's blood vessels. In July 2022, the company performed the world's first implantations in the USA and Australia, and in 2023, it published clinical trial results in Nature, proving that patients were able to control a computer using their thoughts.
  More about Synchron's research on its website.
• DARPA and non-invasive BCI – the U.S. military agency is funding the Next-Generation Nonsurgical Neurotechnology (N3) program, which aims to create non-invasive interfaces, such as high-resolution EEG caps. Although the project is at the prototype stage, its potential – even in military applications – is immense.
  More on the DARPA website.

2. AI for cognitive enhancement: from memory to decision-making

Artificial intelligence does not just connect to the brain – it is increasingly collaborating with it, enhancing or modifying human cognitive abilities. What is the evidence for its effectiveness?

• Memory improvement – in 2022, researchers from the University of Southern California (USC) developed a BCI implant that restored short-term memory in patients with hippocampal damage. The system used AI to boost neuronal signals. A study published in Nature Communications showed memory function improvement in 70% of participants.
  Article in Nature Communications.
• Perception modulation – 2021 research at the University of Toronto showed that BCI interfaces could generate "synthetic light patterns" (phosphenes) through direct stimulation of the visual cortex. Participants in the experiment reported the sensation of "seeing" patterns that had no source in reality.
  Publication in Current Biology.
• Decision-making – in 2023, the Mayo Clinic implemented an AI system (IBM Watson Health) to assist with oncology diagnoses. According to the report, diagnostic errors were reduced by 15%, suggesting that AI can support physicians in clinical decision-making.
  Mayo Clinic press release.

"Today, we are talking about supporting the human brain – not replacing it. The greatest achievements in the field of BCI concern medicine, not the 'enhancement' of healthy individuals."

3. AI-supported gene editing: designing a "better human"?

The final pillar of "human enhancement" is gene editing, where tools like CRISPR combine with AI algorithms to predict protein structures. In December 2023, the FDA approved the first CRISPR-based gene therapy (Casgevy) for the treatment of sickle cell disease. While this is a milestone, the question of "enhancing" healthy people remains open.

Meanwhile, the AlphaFold model from DeepMind, created to predict protein structures, has been used by scientists to design gene therapies. According to Nature, AI has reduced drug design time from several years to several months.

How does AI affect our brain? Facts, myths, and experiments

The promise of "enhancing" humans through AI is based on the assumption that algorithms can modify our cognitive processes. But what is the evidence for this?

Perception: artificial patterns, real sensations

In a 2021 experiment, participants who received direct stimulation of the visual cortex reported the sensation of seeing light patterns. Although they were not "real," the brain interpreted them as external stimuli. This is proof that BCIs can manipulate perception – albeit in a very limited way for now.

Memory: from playback to enhancement

The BCI implant developed by USC does not just play back memory, but strengthens existing neuronal connections. In patients with hippocampal damage, an improvement in information retention of 20–30% was observed. However, this is far from "uploading" new knowledge into the brain.

Decisions: algorithms as a "second mind"

In a 2020 study, MIT researchers demonstrated that AI could predict decisions made by humans with 76% accuracy by analyzing brain activity in real-time. This suggests that in the future, AI could support decision-making – e.g., in medicine or finance. However, ethical concerns regarding responsibility for incorrect decisions remain unanswered.

"The greatest danger is not that AI will replace our brain, but that we will become dependent on it for decision-making. Who will be responsible when an algorithm makes a mistake?"

The ethics of neurotechnology: what awaits us outside the lab?

The integration of AI with the human brain raises questions that go beyond technology. Here are the most serious ones:

1. Mind privacy: will our thoughts become public?

In 2022, researchers from the University of California, San Francisco (UCSF) warned about the possibility of "hacking" BCI interfaces. Brain signals can be intercepted and reconstructed – which means hackers could read our thoughts or even impersonate our intentions. As technology develops, this risk will grow.

2. Social inequality: who will be able to "enhance" themselves?

A 2023 World Economic Forum report indicates that access to neurotechnology (e.g., visual cortex implants) will be limited to wealthy countries and individuals. This could deepen global disparities, creating a new class of "enhanced" and "unenhanced".

3. Identity change: where do we end and the machine begin?

Philosopher Michael Hawley of MIT warns that long-term BCI use could lead to a "blurring of boundaries between the mind and the machine." This is not just a matter of technology, but a fundamental change in the understanding of humanity.

Who is leading the race for "Human 2.0"? Companies and institutions shaping the future

The race to integrate AI with the human brain is happening not only in academic labs but also in the market. Here are the key players and their latest progress:

While Neuralink gets the most media attention, Synchron and DARPA are closer to commercialization. Meanwhile, Cortical Labs offers a completely new perspective on integrating AI with biology.

Timelines in "Human 2.0" visions – what is realistic?

Ray Kurzweil, futurist and Director of Engineering at Google, claims that by 2045, humanity will merge with AI, creating a "technological singularity." But what are the realistic stages of this "change"? Let's look at Pearson's timeline and compare it with the current state of research:

• 2024–2026: Experimental phase (medicine)

  BCIs will be used primarily in medicine – e.g., restoring movement, speech, or vision in people with neurological damage. Neuralink and Synchron are conducting clinical trials, but their scale remains limited.

• 2027–2030: Commercialization phase (non-medical enhancements)

  The first commercial BCI + AI applications will hit the market – e.g., EEG headbands with AI to improve sleep or concentration. Example: Oura Ring already offers memory-support features, albeit to a limited extent.
  Oura Ring research on memory.

• 2030–2035: AI-brain integration (theoretical stage)

  Pearson's predictions assume a direct connection between the brain and the cloud (e.g., Neuralink + large language models), but there is currently no evidence for this. No confirmed progress – most scientists consider this scenario at least a decade away.
  Cortical Labs conducts experiments with "living" neurons, but this is far from full integration.

• 2035–2040: Ethical and regulatory evaluation

  Global regulations (e.g., the EU AI Act) will have to keep pace with the speed of technological development. It is highly likely that strict restrictions on "enhancing" healthy individuals will be introduced.
  EU AI Act draft.

"Pearson and Kurzweil assume linear progress, but reality is more complex. The biggest challenges are not technology, but ethics and regulations."

Alternative voices: what do skeptics say?

Not everyone shares the enthusiasm regarding "enhancing" humans through AI. Here are three key positions:

• Technological skepticism – Prof. Miguel Nicolelis (Duke University)

  "Neurotechnologies are in a development phase similar to aviation in 1900–1910 – commercialization is still a long way off. BCI is the future, but it will not become reality within a decade."

  
  Nicolelis's article in Nature Reviews Neuroscience.
• Ethical concerns – Prof. Rafael Yuste (Columbia University)

  "Integrating AI with the brain is not just a technical issue, but a fundamental change in the understanding of humanity. There is a lack of research on long-term effects."

  
  Yuste's TED talk.
• Business realism – Dr. Bryan Johnson (Kernel)

  "By 2035, people will be able to 'upgrade' their brains, but it won't happen for everyone. It will be a luxury service, available only to a few."

  
  Kernel website.

Regulations: who controls the development of neurotechnology?

Currently, there is no global legal framework for integrating AI with the human brain. Each region has its own approach:

• United States
  • FDA regulates BCIs as medical devices (Class III).
  • DARPA funds military research, but there is no nationwide strategy.
  • In 2023, the Neurotechnology Safety Act was proposed to introduce registration for all BCIs.
• European Union
  • The AI Act (2024) classifies BCIs as "high risk" when integrated with AI.
  • It proposes a ban on experiments without participant consent.
  • This is the most advanced regulatory system, but it is still incomplete.
• China
  • In 2023, Neurotechnology Ethical Guidelines were introduced, banning human experiments without state approval.
  • The Chinese government actively supports the development of neurotechnology, but under strict control.
• Japan and India
  • Japan introduced Guidelines for Neurotechnology (2022), mandating AI algorithm transparency.
  • India is working on a Neurotechnology Policy, but the project is in the early stages.

The lack of a global agreement means that in the future, "neurotechnological powers" may emerge that will shape the future of humanity according to their own interests.

Human 2.0: a revolution in progress – are we ready for it?

The future where AI and neurotechnologies "enhance" humans is no longer a question of if, but when. But are we ready for it – technologically, ethically, and psychologically?

We are currently witnessing the first wave of change:

• Medical BCIs are restoring functions lost to disease.
• AI is supporting memory and decision-making, albeit to a limited extent for now.
• Ethics and regulations are only just emerging – and they will determine the pace of progress.

But the road to "Human 2.0" is paved with challenges:

• Security and privacy of brain data.
• Inequalities in access to technology.
• Fundamental change in the understanding of humanity.

What will the next steps be? Most likely:

1. 2024–2026: Expansion of BCI clinical trials, first commercial applications supporting cognitive functions.
2. 2027–2030: Ethical and regulatory debates will gain momentum, and global agreements will need to be formed.
3. 2030+: If the technology develops, we may face a choice: how far do we want to go in "enhancing" ourselves?

One thing is certain: we will not turn back from this revolution. The only question is whether we can carry it out responsibly.

Sources

• https://youtu.be/Cj1CacXp3zw?si=xzat_zotggedCCgv
• https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-human-trial-brain-computer-interface-neuralink
• https://neuralink.com/updates/
• https://www.synchron.com/news/synchron-achieves-first-in-human-implantation-of-stentrode-in-the-us
• https://www.nature.com/articles/s41586-023-06633-4
• https://www.darpa.mil/program/next-generation-nonsurgical-neurotechnology
• https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-ai-tool-help-diagnose-adults-possible-alzheimers-disease-and-related-dementias
• https://www.nature.com/articles/s41593-022-01168-x
• https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-patients-sickle-cell-disease
• https://www.cell.com/current-biology/fulltext/S0960-9822(20
• https://www.nature.com/articles/s44220-023-00078-8
• https://www.nature.com/articles/s41467-022-31565-1
• https://blog.ouraring.com/science/studies-on-memory-retention